Haleon (NYSE:HLN) Shares Gap Up – Time to Buy?

Haleon PLC Sponsored ADR (NYSE:HLN – Get Free Report)’s stock price gapped up before the market opened on Wednesday. The stock had previously closed at $8.87, but opened at $9.13. Haleon shares last traded at $9.0650, with a volume of 2,350,681 shares traded.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on HLN shares. Wall Street Zen downgraded shares of Haleon from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Morgan Stanley restated an “overweight” rating on shares of Haleon in a research note on Thursday, August 6th. Rothschild & Co Redburn cut Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Zacks Research upgraded Haleon from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Haleon in a report on Wednesday, September 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Check Out Our Latest Research Report on HLN

Haleon Stock Up 2.6%

The firm’s 50-day moving average price is $9.56 and its 200 day moving average price is $9.51. The company has a current ratio of 0.69, a quick ratio of 0.52 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $40.71 billion, a price-to-earnings ratio of 23.73, a PEG ratio of 2.03 and a beta of 0.14.

Haleon Cuts Dividend

The company also recently disclosed a dividend, which was paid on Thursday, September 17th. Shareholders of record on Friday, August 14th were given a dividend of $0.0642 per share. This is a decrease from Haleon’s previous dividend of $0.1307. This represents a yield of 132.0%. The ex-dividend date was Friday, August 14th. Haleon’s dividend payout ratio (DPR) is presently 30.77%.

Institutional Investors Weigh In On Haleon

A number of large investors have recently modified their holdings of the business. Western Wealth Management LLC acquired a new position in shares of Haleon during the 1st quarter worth $29,000. Annis Gardner Whiting Capital Advisors LLC boosted its stake in Haleon by 402.0% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock valued at $30,000 after buying an additional 2,404 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in Haleon by 20.4% in the second quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock valued at $58,000 after buying an additional 1,055 shares in the last quarter. Fiduciary Financial Group LLC bought a new position in Haleon in the second quarter valued at about $97,000. Finally, Gryphon Financial Partners LLC bought a new position in Haleon in the first quarter valued at about $101,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Company Profile

(Get Free Report)

Haleon plc (NYSE: HLN) is a global consumer healthcare company headquartered in Weybridge, England. The company develops, manufactures and markets over-the-counter medicines, oral healthcare products, nutritional supplements and other consumer health products sold through pharmacies, retailers and e-commerce channels.

Its portfolio includes well-known brands such as Sensodyne, Polident and parodontax in oral healthcare; Advil, Panadol, Voltaren and Theraflu in pain relief and respiratory care; and Centrum and Emergen-C in vitamins, minerals and supplements.

Featured Articles

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.